Contineum Therapeutics In... (CTNM)
| Bid | 7.47 |
| Market Cap | 204.68M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -22.06 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.33 |
| Volume | 80,235 |
| Avg. Volume (20D) | 91,398 |
| Open | 7.30 |
| Previous Close | 7.41 |
| Day's Range | 7.06 - 8.13 |
| 52-Week Range | 7.04 - 22.00 |
| Beta | undefined |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Th...
Analyst Forecast
According to 4 analyst ratings, the average rating for CTNM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 277.83% from the latest price.
2 months ago · businesswire.com
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx ConferenceSAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small m...